检测EB病毒TK激酶抗体方法的建立及其在鼻咽癌诊断中的应用

目的:建立检测鼻咽癌(NPC)患者血清中EB病毒TK激酶的酶免疫测定(EIA)方法,用于筛选和辅助诊断早期NPC患者。方法:用基因工程高效表达的EB病毒TK激酶作为包被抗原,建立EIA检测方法,检测NPC患者和对照血清中的TK/IgG抗体。结果:在NPC患者血清中检出了特异的对EB病毒TK激酶的IgG抗体,而正常人血清中为抗体阴性。结论:首先建立了简便、快速、特异和敏感的早期诊断NPC的EIA方法,并作为我公司产品扩展应用。     

整合REV LTR序列的MDV弱毒株的分离鉴定与生物学特性

【目的】从非免疫健康三黄鸡中分离到一株马立克氏病病毒(MDV),命名为MDV GD06株,本工作系统研究了其生物学特性。【方法】PCR扩增GD06株Meq基因及短末端重复区(RS)序列,进行序列分析,并用间接免疫荧光试验进行血清型特异性鉴定;通过接种SPF鸡和鸡胚成纤维细胞(CEF)来判定GD06株体内外的增殖能力;为确定GD06株的致病性,用1日龄SPF鸡进行攻毒试验。【结果】GD06株为MDV血清I型病毒,其基因组中自然整合禽网状内皮增殖症病毒(REV)的长末端重复序列(LTR),Meq基因富含脯氨酸的结构域比参考强毒株Md5多59个氨基酸,与MD商品化疫苗CVI988/Rispens和814株相符,具有弱毒株的特征。在接种CEF细胞96、120、144、168、192 h,GD06株病毒滴度分别为1.9×105、3.9×105、6.1×105、6.5×105、5.8×105PFU,明显比CVI988/Rispens(病毒滴度分别为1.3×105、3.5×105、5.0×105、5.7×105、4.7×105PFU)高(P0.05);接种SPF鸡21、28天,GD06株在鸡体内的病毒滴度分别为740和350 PFU,明显比CVI988/Rispens株(病毒滴度分别为460、216 PFU)高(P0.05),结果表明,GD06株在CEF细胞和鸡体内具有比CVI988/Rispens更快的增殖能力。人工接种攻毒实验表明,GD06株对SPF鸡没有致病性,不引免疫抑制。【结论】研究结果表明,MDV GD06株为国内首次分离的自然整合有REV LTR序列的重组MDV弱毒株。     

黄瓜DAMD反应体系的建立及种质遗传资源研究

通过L16(45)正交试验,研究Mg2+、dNTPs、Taq酶、引物和模板DNA对黄瓜DAMD(direct amplificationof minisatellite region DNA)反应的影响.结果表明,适宜的DAMD反应体系包括1×Taq酶缓冲液、1.5 mmol/LMg2+、0.25 mmol/L dNTPs、1.2 UTaq酶、2.0μmol/L引物和10~80 ng模板DNA,总体积20μL.采用该体系并结合温度梯度PCR,确定了15种小卫星核心DNA引物的适宜退火温度.利用这些引物对20份不同类型的黄瓜材料进行扩增,引物平均检测到10.2个位点,平均多态性位点7.3个,平均多态性百分率71.4%.PCA分析表明,20份材料明显可分为3个区域,第I区包含绝大部分华南型黄瓜,第II区包含绝大部分华北型黄瓜,第III区为野生型黄瓜.此结果与SSR标记的研究结果基本一致,证明本实验构建的DAMD反应体系的稳定性及DAMD标记的可行性.     

B3(ds-scFv)靶向超抗原的制备及活性鉴定

To construct the expression vector of a recombinant toxin composed of a disulfide stable single-chain antibody from mAbB3 and SEA(D227A),the binding ability and cytotoxicity of the purified renatured products against the B3 positive carcinoma cells was examined. The VH and VL fragments of the mAbB3 were ligated by overlap PCR, the PCR product was cloned to the pET22b expression vector, then the SEA fragment was inserted into the B3dsscFv-pET22b expression vector which was digested by the same restriction enzymes. The expression plasmid was identified by restriction endonucleases digestion and transformed into E.coli BL21(DE3) followed by IPTG induction. The inclusion body was purified through SP-Sepharose cation exchange column after denaturing and refolding and the binding and cytotoxic ability of the purified products was examined by cell-ELISA and non-radioactive cell proliferation assay seperately. The expression vector B3dsscFv-SEA-pET was constructed successfully and the expression product exists mainly in the inclusion body, amounting to 33% of the total protein. The refolding product remains the binding ability of the single-chain antibody and has cytotoxic effect on HT-29 colon carcinoma cells. The stability assay showed that the resulting protein was stable at 37℃. This genetically engineered B3dsscFv-SEA fusion protein has bifunction of tumor targeting and tumor cell killing and promises to be an effective reagent for tumor targeted immunotherapy.